Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank Disease ID
1 Coronavirus disease - COVID-19 💬
[2] JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
2 Coronavirus disease - COVID-19 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
3 Epstein-Barr virus infection 💬
[3] JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
4 Epstein-Barr virus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
5 Hepatitis B 💬
[4] JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
6 Hepatitis B 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
7 Hepatitis C 💬
[2] JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
8 Hepatitis C 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
9 Herpes simplex virus 1 infection 💬
[3] JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
10 Herpes simplex virus 1 infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
11 Human papillomavirus infection 💬
[2] JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
12 Human papillomavirus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
13 Influenza A 💬
[3] JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
14 Influenza A 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
15 JAK-STAT signaling pathway 💬
[4] JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
16 JAK-STAT signaling pathway 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
17 Kaposi sarcoma-associated herpesvirus infection 💬
[3] JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
18 Kaposi sarcoma-associated herpesvirus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
19 Measles 💬
[3] JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
20 Measles 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
21 Necroptosis 💬
[4] JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
22 Necroptosis 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
23 NOD-like receptor signaling pathway 💬
[2] JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
24 NOD-like receptor signaling pathway 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
25 Osteoclast differentiation 💬
[2] JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
26 Osteoclast differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
27 Th1 and Th2 cell differentiation 💬
[4] JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
28 Th1 and Th2 cell differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
29 Th17 cell differentiation 💬
[4] JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
30 Th17 cell differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬
31 Toxoplasmosis 💬
[3] JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
32 Toxoplasmosis 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [3] 49, 96, 97 💬